Biomarin Pharmaceutical Inc
XMUN:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biomarin Pharmaceutical Inc
XMUN:BM8
|
US |
|
C
|
Canopy Growth Corp
F:11L1
|
CA |
Wall St Price Targets
BM8 Price Targets Summary
Biomarin Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for BM8 is 78.1 EUR with a low forecast of 46.81 EUR and a high forecast of 106.18 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BM8's stock price target?
Price Target
78.1
EUR
According to Wall Street analysts, the average 1-year price target for BM8 is 78.1 EUR with a low forecast of 46.81 EUR and a high forecast of 106.18 EUR.
What is the Revenue forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 15%.
What is the Gross Profit forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 15%.
What is the Operating Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
28%
The compound annual growth rate for Operating Income over the next 3 years is 28%.
What is the Pre-Tax Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
53%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 53%.
What is the Net Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
60%
The compound annual growth rate for Net Income over the next 3 years is 60%.
